ADOCIA Announces the Availability of a Prospectus for the Admission to Trading of Shares Issued or Likely to Be Issued to IPF Partners on Exercise of Its Warrants
13 Septiembre 2023 - 2:34PM
Business Wire
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage
biopharmaceutical Company focused on the research and development
of innovative therapeutic solutions for the treatment of diabetes
and obesity (the “Company”), announces today the
availability of a second amendment to its 2022 Universal
Registration Document, filed by the Company with the Autorité des
Marchés Financiers ("AMF") on September 13, 2023, under
number D.23-0346-A02, and an admission Prospectus approved by the
AMF on September 13, 2023, under number 23-392, in connection with
the admission to trading on the regulated market of Euronext Paris
of new ordinary shares issued or likely to be issued to IPF
Partners on exercise of its warrants (bons de souscription
d’actions or "Warrants").
The Prospectus comprises:
- the 2022 Universal Registration Document
filed by the Company with the AMF on April 26, 2023, under number
D.23-0346; - the first amendment to the 2022 Universal Registration
Document filed by the Company with the AMF on July 26, 2023 under
number D.23-0346-A01; - the second amendment to the 2022 Universal
Registration Document filed by the Company with the AMF on
September 13, 2023 under number D.23-0346-A02; - the Securities
Note; and - the Prospectus summary (included in the Securities
Note).
These documents can also be consulted on the Company's website
(www.adocia.com) and on the AMF website (www.amf-France.org).
About Adocia
Adocia is a biotechnology Company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on
four proprietary technology platforms:
1) The BioChaperone® technology for the development of new
generation insulins and products combining insulins with other
classes of hormones; 2) AdOral®, an oral peptide delivery
technology; 3) AdoShell®, an immunoprotective biomaterial for cell
transplantation, with a first application in pancreatic cells
transplantation; 4) AdoGel®, a long-acting drug delivery
platform.
Adocia holds more than 25 patent families. Based in Lyon, the
Company has about 100 employees. Adocia is listed on the regulated
market of EuronextTM Paris (Euronext: ADOC; ISIN:
FR0011184241).
Disclaimer
This press release and the information it contains do not
constitute an offer to sell or subscribe, or the solicitation of an
order to buy or subscribe, Adocia shares in any country. The
distribution of this press release may be restricted by certain
local laws. Recipients of this press release are required to inform
themselves of any such restrictions and, where applicable, to
comply with them.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230913400829/en/
Adocia Olivier Soula CEO
contactinvestisseurs@adocia.com Tel : +33 4 72 610 610
www.adocia.com
Adocia Press and Investors Relations Ulysse Communication
Pierre-Louis Germain Bruno Arabian +33 (0)6 64 79 97
51 adocia@ulysse-communication.com
Edoc Acquisition (NASDAQ:ADOC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Edoc Acquisition (NASDAQ:ADOC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024